Arvinas company information, Employees & Contact Information

Arvinas Presents Preclinical Data for ARV-806 Demonstrating GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences Yahoo Finance

Arvinas, Inc. to Present Clinical Data for Investigational PROTAC LRRK2 Degrader ARV-102 at MDS 2025 Conference Quiver Quantitative

Arvinas to Present Preclinical Data for ARV-806, a PROTAC GlobeNewswire

ARVN - Arvinas Announces Retirement of Chief Executive Officer and Succession Plan ADVFN

97% LRRK2 Reduction — Arvinas' ARV-102 Shows Strong PBMC Target Engagement and CSF Biomarker Modulation Stock Titan

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer Pfizer

Arvinas to Present Data from the Vepdegestrant Clinical GlobeNewswire

Arvinas Presents Late Breaking, Positive Phase 1 Clinical GlobeNewswire

Arvinas to Present Clinical Data for ARV-102, a PROTAC GlobeNewswire

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation GlobeNewswire

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Arvinas Announces FDA Acceptance of the New Drug GlobeNewswire

First-Ever PROTAC LRRK2 Degrader Human Trial Data: Arvinas Reveals Breakthrough Parkinson's Results Stock Titan

Clinical-Stage Protein Degradation Pioneer Arvinas to Share Updates at Major Healthcare Conferences Stock Titan

Arvinas, Inc. to Host Q2 2025 Financial Results and Corporate Update Webcast on August 6, 2025 Quiver Quantitative

Arvinas to Present Preclinical Data for PROTAC BCL6 GlobeNewswire

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development Stock Titan

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial GlobeNewswire

Arvinas Shares New Preclinical Combination Data for the GlobeNewswire

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation GlobeNewswire

Protein Degradation Pioneer Arvinas Announces Q1 2025 Earnings Date and Webcast Details Stock Titan

Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case Seeking Alpha

First-Ever PROTAC Cancer Drug Heads to FDA: Arvinas' Breakthrough Breast Cancer Treatment Stock Titan

Arvinas, Inc. to Host Live Webcast for Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 11, 2025 Quiver Quantitative

Arvinas Updates Guidance for First- and Second-Line Phase 3 GlobeNewswire

Physicochemical Property Determinants of Oral Absorption for PROTAC Protein Degraders ACS Publications

Arvinas Enters into a Transaction with Novartis, including GlobeNewswire

Arvinas and Pfizer Announce Updated Clinical Data from GlobeNewswire

Arvinas Appoints Everett Cunningham to Board citybiz

Delivering on a Promise: The Present and Future of Targeted Protein Degradation Genetic Engineering and Biotechnology News

Arvinas and Pfizer Announce Global Collaboration to Develop GlobeNewswire

Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven GlobeNewswire

Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio GlobeNewswire

Arvinas Completes $55 Million Series C Financing to Advance Protein Degradation Platform PR Newswire